Open Access
CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S89
DOI: 10.1055/s-0038-1640020
Abstracts
Onkologie: Oncology

Antibodies to tumor-associated antigens in non-recurrent and recurrent disease head and neck squamous cell carcinomas (HNSCC) patients

DS Gangkofner
1   Universitätsklinik Ulm, HNO-Klinik, Ulm
,
D Holzinger
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
J Butt
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
I Zörnig
3   NCT, DKFZ, Universitätsklinik Heidelberg, Heidelberg
,
M Broglie Däppen
4   Kantonsspital St. Gallen, HNO-Klinik, St. Gallen, Schweiz
,
G Dyckhoff
5   Universitätsklinik Heidelberg, HNO-Klinik, Heidelberg
,
P Boscolo-Rizzo
6   Universitätsklinik Padua, Abteilung für Neurowissenschaften, Treviso, Italien
,
G Wichmann
7   Universitätsklinik Leipzig, HNO-Klinik, Leipzig
,
M Pawlita
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
S Laban
1   Universitätsklinik Ulm, HNO-Klinik, Ulm
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 
 

    Background:

    Previously, we have discovered an association between MAGE-/NY-ESO-1 expression and poor overall survival in HNSCC patients. Using multiplex serology, we have now analyzed patterns of antibody (AB) responses to tumor-associated antigens (TAA) in non-recurrent (NR) and recurrent disease (RD) head and neck squamous cell carcinomas (HNSCC) patients.

    Methods:

    Plasma- and serum samples of 410 HNSCC patients treated at different cancer centers were analyzed for AB to 29 auto-antigens and HPV-16 E6 using multiplex serology. Among 319 patients with available recurrence status, 235 were NR and 84 had RD. Statistics: Antibody prevalences were compared using a Chi2-test. A correction for multiple testing was performed using the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli with a false discovery rate von 10%.

    Results:

    Among 235 NR patients, 82 (35%) were seropositive for HPV-16 E6. AB found most frequently were directed against MAGE-A3 (12%), MAGE-A4 (12%), SpanXa1 (11%), p53 (11%), and MAGE-A1 (10%). Among 84 RD pt, 18 (21%) were seropositive for HPV-16 E6. Antibody reactivity to MAGE-A3 (19%), MAGE-A4 (13%), SpanXa1 (12%), p53 (12%), MAGE-A1 (12%), c-myc (11%), Recoverin (11%) and MAGE-A9 (10%) was found most frequently. In RD patients, AB against MAGE-C2 were significantly more frequent (NR: 2% vs. RD: 8%; p = 0.010, Chi2-Test) and AB to HPV-16 E6 significantly less frequent (p = 0.014). Corrected for multiple testing, the p-values did not reach significance.

    Conclusions:

    AB to TAA in NR and RD patients are directed against the same antigens. Data analysis is ongoing.


     

    No conflict of interest has been declared by the author(s).

    Dominik Stefan Gangkofner
    Universitätsklinik Ulm, HNO-Klinik,
    Frauensteige 12, 89075,
    Ulm

    Publikationsverlauf

    Publikationsdatum:
    18. April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York